HC Wainwright Has Bearish Estimate for BHST FY2029 Earnings

Key Points

• HC Wainwright cut its FY2029 EPS estimate for BioHarvest Sciences (BHST) to $0.80 from $1.00, according to analyst A. Dayal in a note dated April 14.
• The MarketBeat consensus for the current full year is a negative $0.80 EPS while the stock's consensus rating is Hold with a $12.50 price target, showing a mismatch between near-term consensus and HC Wainwright's outlook.
• BHST is trading around $4.27 (1‑year range $4.10–$12.80) with a market cap of about $83.8M, a negative P/E, and recent small institutional purchases reported.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities researchers at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a note issued to investors on Tuesday, April 14th. HC Wainwright analyst A. Dayal now anticipates that the company will earn $0.80 per share for the year, down from their previous estimate of $1.00. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share.

BHST has been the topic of several other reports. Roth Mkm began coverage on BioHarvest Sciences in a research note on Thursday, February 19th. They issued a "buy" rating and a $10.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $12.50.

BioHarvest Sciences Trading Down 0.2%

BHST stock opened at $4.27 on Wednesday. BioHarvest Sciences has a 1-year low of $4.10 and a 1-year high of $12.80. The firm has a market cap of $83.78 million, a P/E ratio of -7.00 and a beta of 1.16. The business's 50 day moving average is $4.45 and its 200-day moving average is $6.26. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On BioHarvest Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in BioHarvest Sciences in the fourth quarter worth $60,000. Geode Capital Management LLC bought a new stake in shares of BioHarvest Sciences during the fourth quarter worth $61,000. HRT Financial LP bought a new stake in shares of BioHarvest Sciences during the fourth quarter worth $75,000. Marshall Wace LLP bought a new stake in shares of BioHarvest Sciences during the fourth quarter worth $110,000. Finally, Quadrature Capital Ltd bought a new stake in shares of BioHarvest Sciences during the fourth quarter worth $140,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.